Lung trials now recruiting patients
Our lung cancer trials are focused on the benefits and side effects of radiotherapy.
TROG 17.02 (OUTRUN) - The aim of this study is to compare the effects of Osimertinib alone versus Osimertinib plus Stereotactic Radiosurgery (SRS) on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.
Primary sponsor: TROG
TROG 16.03 (CORE) - This study aims to show that the addition of SBRT (stereotactic body radiotherapy) to standard of care improves progression-free survival for patients with extra-cranial oligometastatic disease that has spread from their lung, breast and/or prostate cancer.
Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG
TROG 16.01 (NIVORAD) - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.
Primary sponsor: The University of Sydney
Collaborating groups: ALTG and TROG